Fig. 6: Inhibition of MCL1 slows growth of CDS xenograft tumors in vivo.
From: Patient-derived tumoroids from CIC::DUX4 rearranged sarcoma identify MCL1 as a therapeutic target
a Ratio of IC50 values for 244 drugs determined with CDS-ZH003 cells in presence or absence of 1 nM S64315. Drug classes showing high cooperativity with S64315 are highlighted in red (BCL2-family inhibitors), blue (bromodomain inhibitors), and pink (PI3K inhibitors). n = 2 independent experiments. b Combination matrix used to test the synergy between the MCL1 inhibitor S64315 and the BCL2 inhibitor venetoclax. The relative number of viable CDS-ZH003 cells as determined by image-based analysis after 72 h of treatment is depicted. n = 2 independent experiments. c Bliss synergy scores for the indicated CDS models after treatment with S64315 in combination with different chemotherapeutics, venetoclax or PQR514 for 72 h. Calculation was based on the number of viable cells, determined by image-based analysis. n = 2 independent experiments. d Growth curves of xenograft tumors in individual female mice transplanted with CDS-ZH001 cells and treated twice a week with either vehicle (black) or 20 mg/kg S64315 (red) (upper panel). Black triangles indicate the time points of drug application. Survival curves calculated with the data from the upper panel (lower panel). Log-rank (Mantel-Cox) test. Source data are provided as a Source Data file.
